Comparative study of quetiapine combined MECT on the treatment of female refractory schizophrenia

OBJECTIVE: To investigate quetiapine combined modified electric convulsive therapy (MECT) clinical efficacy and safety of women with refractory schizophrenia. METHODS: 62 female patients with refractory schizophrenia were randomly divided into two groups, the study group (31 cases ), oral quetiapine based on the use MECT treatment and control group (31 cases), clozapine treatment, 8 weeks, before treatment and at 2 weeks, 4 weeks, 6 weeks, 8 weeks using the positive and negative Syndrome scale, to assess the clinical efficacy, adverse side effects rating scale from 2 weeks before the results of the treatment of positive symptoms factor score decreased significantly compared with treatment (P <0.05);. treatment from 4 weekend, two positive and negative symptoms of the amount table total score and factor scores than those there before treatment significantly decreased (P <0.05 or 0.01); the treatment of various periods Rating study group than the control group decreased significantly, but there was no significant difference (P> 0.05); the treatment of 8 weeks, study group was 71.2%, the control group was 66.7%, there was no significant difference (P> 0.05). CONCLUSION: quetiapine combined MECT treatment of female refractory schizophrenics with clozapine rather, but comparing clozapine faster, safer, and medication compliance is greatly improved.